Secondary male hypogonadism induced by sellar space-occupying lesion: Clinical analysis of 22 cases.
- Author:
Hong-Lei LU
1
;
Tao WANG
1
;
Hao XU
1
;
Li-Ping CHEN
1
;
Ke RAO
1
;
Jun YANG
1
;
Hui-Xing YUAN
1
;
Ji-Hong LIU
1
Author Information
- Publication Type:Journal Article
- Keywords: human chorionic gonadotrophin; hyperprolactinemia; testosterone undeconoate; secondary male hypogonadism; sellar space-occupying lesion
- MeSH: Adult; Chorionic Gonadotropin; therapeutic use; Follicle Stimulating Hormone; blood; Humans; Hypogonadism; diagnosis; etiology; therapy; Luteinizing Hormone; blood; Male; Pituitary Neoplasms; blood; complications; pathology; therapy; Prolactinoma; blood; complications; pathology; therapy; Retrospective Studies; Sella Turcica; Spermatogenesis; Spermatozoa; Testis; anatomy & histology; drug effects; Testosterone; analogs & derivatives; blood; therapeutic use; Tumor Burden
- From: National Journal of Andrology 2016;22(8):704-709
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo analyze the clinical characteristics of secondary male hypogonadism induced by sellar space-occupying lesion, explore its pathogenesis, and improve its diagnosis and treatment.
METHODSWe retrospectively analyzed the clinical data about 22 cases of secondary male hypogonadism induced by sellar space-occupying lesion, reviewed related literature, and investigated the clinical manifestation, etiological factors, and treatment methods of the disease. Hypogonadism developed in 10 of the patients before surgery and radiotherapy (group A) and in the other 12 after it (group B). The patients received endocrine therapy with Andriol (n=7) or hCG (n=15).
RESULTSThe average diameter of the sellar space-occupying lesions was significantly longer in group A than in B (［2.35±0.71］ vs ［1.83±0.36］ cm, P<0.05) and the incidence rate of prolactinomas was markedly higher in the former than in the latter group (60% vs 0, P<0.01). The levels of lutein hormone (LH), follicle stimulating hormone (FSH) and testosterone (T) were remarkably decreased in group B after surgery and radiotherapy (P<0.01). Compared with the parameters obtained before endocrine therapy, all the patients showed significant increases after intervention with Andriol or hCG in the T level (［0.78±0.40］ vs ［2.71±0.70］ ng/ml with Andriol; ［0.93±0.44］ vs ［3.07±0.67］ ng/ml with hCG) and IIEF-5 score (5.00±2.61 vs 14.50±3.62 with Andriol; 5.36±1.82 vs 15.07±3.27 with hCG) (all P<0.01). The testis volume increased and pubic hair began to grow in those with hypoevolutism. The patients treated with hCG showed a significantly increased testis volume (P<0.01) and sperm was detected in 7 of them, whose baseline testis volume was markedly larger than those that failed to produce sperm (［11.5±2.3］ vs ［7.5±2.3］ ml, P<0.01). Those treated with Andriol exhibited no significant difference in the testis volume before and after intervention and produced no sperm, either.
CONCLUSIONSHypothyroidism might be attributed to surgery- or radiotherapy-induced damage to the pituitary tissue, space-occupying effect of sellar lesion, and hyperprolactinemia. Both Andriol and hCG can improve the T level and erectile function, but the former does not help spermatogenesis.
